According to a new report, published by KBV research, The Global Vulvovaginal Candidiasis Treatment Market size is expected to reach $1.3 billion by 2028, rising at a market growth of 4.6% CAGR during the forecast period.
The Online Pharmacy market is experiencing a CAGR of 5.6% during (2022 - 2028). A vast proportion of patients prefer online pharmacy instead of choosing to go to offline pharmacy stores. Furthermore, the emergence of various online pharmacy stores, such as Netmeds, is further supporting the sale of VVC treatment drugs through online stores, thereby contributing to the market expansion.
The Oral market is leading the segment in the Global Vulvovaginal Candidiasis Treatment Market by Route of Administration in 2021; thereby, achieving a market value of $582.8 million by 2028. This is due to the convenience of this route of administration for azoles, high availability, and utilization of anti-fungal drugs. In addition, oral fluconazole is the drug used most for prescription drugs recommended for treatment in maintenance therapy.
The Clotrimazole market is registering a CAGR of 5.1% during (2022 - 2028). The growth is the result of unremarkable side effects and an uncomplicated metabolic profile, and clotrimazole has gained traction for the treatment of infections such as vulvovaginal candidiasis. Further, the clotrimazole drug has undergone various research-related activities, resulting in its rising popularity.
The North America market dominated the Global Vulvovaginal Candidiasis Treatment Market by Region in 2021; thereby, achieving a market value of $479.2 million by 2028. The Europe market is poised to grow at a CAGR of 4.2% during (2022 - 2028). Additionally, The Asia Pacific market would witness a CAGR of 5.3% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/vulvovaginal-candidiasis-treatment-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Bayer AG, Bristol Myers Squibb Company, Pfizer, Inc., Astellas Pharma, Inc., Mycovia Pharmaceuticals, Inc. (NovaQuest Capital Management,LLC), Basilea Pharmaceutica Ltd., Scynexis, Inc. and Grupo Ferrer Internacional S.A.
By Distribution Channel
By Route of Administration
By Drug Class
Companies Profiled
Unique Offerings 
